Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab [version 2; peer review: 2 approved]

The cornerstone of inflammatory bowel disease (IBD) treatment is immunomodulators. IBD patients are at increased risk of intestinal and extraintestinal malignancy. Ustekinumab is a fully humanized monoclonal anti-IL12/23 antibody with a good safety profile. Malignancies of breast, colon, head and ne...

Full description

Bibliographic Details

Published in:	F1000Research
Main Authors:	Georgios Axiaris, Leonidas Marinos, Marina Papoutsaki, Alexandros Ioannou, Spyridon Michopoulos, Michael Liontos, Evanthia Zampeli
Format:	Article
Language:	English
Published:	F1000 Research Ltd 2023-10-01
Subjects:	Melanoma IBD Crohn’s disease Ustekinumab eng
Online Access:	https://f1000research.com/articles/11-424/v2